Posted by Michael Wonder on 17 Apr 2023
Olaparib in metastatic prostate cancer: added benefit for certain patients
17 April 2023 - Younger treatment naïve patients benefit. No relevant data were presented for previously treated patients.
In an early benefit assessment, the German IQWiG has examined whether the combination of abiraterone and prednisone or prednisolone can improve adults with metastatic castration-resistant prostate cancer for whom chemotherapy is not indicated when compared to the appropriate comparator therapy.
